Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - CELGENE CORP /DE/ | c12823e8vk.htm |
| EX-99.1 - EX-99.1 - CELGENE CORP /DE/ | c12823exv99w1.htm |
Exhibit 99.2
Contact:
| Jacqualyn A. Fouse | Tim Smith | |||
| Sr. Vice President and | Director | |||
| Chief Financial Officer | Investor Relations | |||
| Celgene Corporation | Celgene Corporation | |||
| (908) 673-9956 | (908) 673-9951 |
CELGENE ANNOUNCES ADDITIONAL $1 BILLION SHARE
REPURCHASE PROGRAM
REPURCHASE PROGRAM
SUMMIT, NJ — (February 16, 2011) — Celgene Corporation (NASDAQ: CELG) today announced that the
company’s Board of Directors has authorized the repurchase of up to an additional $1 billion of the
Company’s common stock through December 2012. This authorization is in addition to the $500
million authorization announced on January 10, 2011. The $500 million program announced in April of
2009 has been fully utilized.
Purchases may be made in the open market or in privately negotiated transactions from time to time,
as determined by Celgene’s management and in accordance with the requirements of the Securities and
Exchange Commission. As of December 31, 2010, Celgene had 470,388,164 shares of common stock
outstanding.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical
company engaged primarily in the discovery, development and commercialization of novel therapies
for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit the company’s Web site at www.celgene.com.
This release contains certain forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company’s control. The Company’s actual
results, performance, or achievements could be materially different from those projected by these
forward-looking statements. The factors that could cause actual results, performance, or
achievements to differ from the forward-looking statements are discussed in the Company’s filings
with the Securities and Exchange Commission, such as the Company’s Form 10-K, 10-Q and 8-K reports.
Given these risks and uncertainties, you are cautioned not to place undue reliance on the
forward-looking statements.
# # #